1308 related articles for article (PubMed ID: 35172054)
1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
2. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
4. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
[TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
Anderson AS; Caubel P; Rusnak JM;
N Engl J Med; 2022 Sep; 387(11):1047-1049. PubMed ID: 36069818
[No Abstract] [Full Text] [Related]
6. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
Cao B; Wang Y; Lu H; Huang C; Yang Y; Shang L; Chen Z; Jiang R; Liu Y; Lin L; Peng P; Wang F; Gong F; Hu H; Cheng C; Yao X; Ye X; Zhou H; Shen Y; Liu C; Wang C; Yi Z; Hu B; Xu J; Gu X; Shen J; Xu Y; Zhang L; Fan J; Tang R; Wang C
N Engl J Med; 2024 Jan; 390(3):230-241. PubMed ID: 38231624
[TBL] [Abstract][Full Text] [Related]
7. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
Hammond J; Fountaine RJ; Yunis C; Fleishaker D; Almas M; Bao W; Wisemandle W; Baniecki ML; Hendrick VM; Kalfov V; Simón-Campos JA; Pypstra R; Rusnak JM
N Engl J Med; 2024 Apr; 390(13):1186-1195. PubMed ID: 38598573
[TBL] [Abstract][Full Text] [Related]
8. Paxlovid for treatment of COVID-19.
Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
[No Abstract] [Full Text] [Related]
9. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
Charness ME; Gupta K; Stack G; Strymish J; Adams E; Lindy DC; Mohri H; Ho DD
N Engl J Med; 2022 Sep; 387(11):1045-1047. PubMed ID: 36069968
[No Abstract] [Full Text] [Related]
10. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
11. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
Rubin R
JAMA; 2022 Jun; 327(24):2380-2382. PubMed ID: 35675094
[No Abstract] [Full Text] [Related]
12. An oral SARS-CoV-2 M
Owen DR; Allerton CMN; Anderson AS; Aschenbrenner L; Avery M; Berritt S; Boras B; Cardin RD; Carlo A; Coffman KJ; Dantonio A; Di L; Eng H; Ferre R; Gajiwala KS; Gibson SA; Greasley SE; Hurst BL; Kadar EP; Kalgutkar AS; Lee JC; Lee J; Liu W; Mason SW; Noell S; Novak JJ; Obach RS; Ogilvie K; Patel NC; Pettersson M; Rai DK; Reese MR; Sammons MF; Sathish JG; Singh RSP; Steppan CM; Stewart AE; Tuttle JB; Updyke L; Verhoest PR; Wei L; Yang Q; Zhu Y
Science; 2021 Dec; 374(6575):1586-1593. PubMed ID: 34726479
[TBL] [Abstract][Full Text] [Related]
13. Nirmatrelvir-ritonavir for COVID-19.
McDonald EG; Lee TC
CMAJ; 2022 Feb; 194(6):E218. PubMed ID: 35115376
[No Abstract] [Full Text] [Related]
14. Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.
Kuehn BM
JAMA; 2022 Jul; 328(4):323. PubMed ID: 35881113
[No Abstract] [Full Text] [Related]
15. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
16. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
[TBL] [Abstract][Full Text] [Related]
17. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
[TBL] [Abstract][Full Text] [Related]
18. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
19. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
20. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
